Imagin Medical – The Next Generation Ultrasensitive Imaging Solutions for Early Detection and Treatment of Cancer

 

Imagin Medical Inc. is a medical imaging company positioned to radically improve the way physicians detect cancer through the use of endoscopes. The Company is developing the i/Blue Imaging System which they believe will help reduce the recurrence of bladder cancer. This technology will increase urologists’ ability to remove all cancerous cells through an endoscope (cystoscope) by dramatically improving the ability to visualize suspicious masses. Imagin’s system’s unique combination of optical/laser technologies projects white light and near-infrared fluorescence through the scope to increase the imaging sensitivity, greatly reduce the dosage of chemical agents and blend the images so that only one monitor is required during surgery. The i/Blue Imaging System can be seamlessly adapted to most endoscope on the market today.

 

The company’s products are based on the invention of Dr. Stavros Demos from the Lawrence Livermore National Laboratory (LLNL). Dr. Stavros worked in collaboration with the UC Davis Comprehensive Cancer Center and Dr. Ralph deVere White, one of the world’s leading authorities on bladder cancer, for more than five years to prove feasibility. IME has entered into a partnership with the LLNL and UC Davis to complete additional clinical evaluations that will support their FDA submission.

 

 

Latest News Release

Imagin Medical 2017 Mid-Year Update

Imagin Medical Inc. today released a mid-year report to keep investors and interested parties informed of the company's progress.

 

Overview

 

As previously reported, it is anticipated that the internal review board (IRB) at the University of Rochester will soon consider the proposal for the first in-human research study using the i/Blue imaging system to be conducted at its affiliated medical centre. Approval is expected early in third quarter. Based on previous bench testing, the company expects that results from the study will be positive and will accelerate the momentum of Imagin's progress to date.

 

The company has completed the prototype to be used in the study and, as a result, has significantly reduced its monthly cash requirements. Further optimization of the prototype will continue after the human trials have been completed.

 

Recent industry discussions concerning the limitations of today's bladder cancer detection systems have reinforced Imagin's confidence that the timing of the i/Blue system is ideal and the technology will significantly enhance the current methodology. The company predicts the medical marketplace will enthusiastically embrace its introduction and that Imagin will build a valuable company with multiple exit strategies.

 

University of Rochester internal review board approval clinical research study

 

Obtaining an IRB approval at a major academic medical centre is a complex process. While typical scheduling procedures have delayed the final IRB approval for the i/Blue imaging system research study, protocols to direct the study are in place and ready to be implemented when approval is received. The University of Rochester IRB boards are guided by the ethical principles described in the Belmont Report and by the regulations of the U.S. Food and Drug Administration, and the U.S. Department of Health and Human Services. The University of Rochester reviews, approves the initiation of and conducts periodic reviews of research involving human subjects. These steps will assure the appropriate credibility for Imagin Medical's first in-human study, which is anticipated in the very near future.

 

Imagin is confident that the 10-patient study will validate the bench-testing results that have shown: (1) physicians will be able to see the cancer in 10 minutes versus one hour required by today's technology; and (2) the white and florescence images will blend into one to put the cancer into context within the bladder.

 

American Urological Association (AUA) meeting

 

This year's AUA annual meeting was held in Boston from May 11 to May 15, with over 10,000 urologists in attendance. Imagin executives met with members of the company's scientific advisory board, all of whom were very encouraged by conference presentations and discussions which confirmed their belief that the company's technology and strategy are well timed to bring new standard of care in bladder cancer. Imagin executives also met with several physicians from high-profile medical institutions who expressed interest in the i/Blue system and in working with the company during its testing period and beyond.

 

Summary

 

Imagin Medical believes its innovative and timely technology will disrupt large markets for not only bladder cancer detection, but also other minimally invasive surgeries where endoscopes are used. With additional financing going forward and the support of a major university and medical centre for further development and evaluation, the company believes it is well positioned to launch the i/Blue imaging system on schedule. The company also believes the current stock price presents an opportunity for significant value and multiple liquidity options. Management looks forward to building Imagin into a profitable company that will provide the medical community with tools to advance cancer detection and reduce recurrence rates.

 

About Imagin Medical Inc.

 

Imagin Medical is developing imaging solutions for the early detection of cancer and improved visualization through the use of endoscopes. The company believes it will radically improve the way physicians detect cancer and view the surgical field. Imagin's initial target market is bladder cancer, a major cancer worldwide, the sixth most prevalent in the United States and the most costly cancer to treat due to a greater than 50-per-cent recurrence rate. Developed at the Lawrence Livermore National Laboratory, this advanced, ultrasensitive imaging technology is based upon improved optical designs and advanced light sensors.


ON BEHALF OF THE BOARD:


Jim Hutchens,

President & CEO


For further information, contact:

Bill Galine, Investor Relations

Telephone: (775) 737-3292

Email: billgaline@gmail.com

 

Legal Notice / Disclaimer

 

This document is not and should not be construed as an offer to sell or the solicitation of an offer to purchase or subscribe for any investment.

 

Richard Mills has based this document on information obtained from sources he believes to be reliable but which has not been independently verified.

 

Richard Mills makes no guarantee, representation or warranty and accepts no responsibility or liability as to its accuracy or completeness. Expressions of opinion are those of Richard Mills only and are subject to change without notice. Richard Mills assumes no warranty, liability or guarantee for the current relevance, correctness or completeness of any information provided within this Report and will not be held liable for the consequence of reliance upon any opinion or statement contained herein or any omission.

 

Furthermore, I, Richard Mills, assume no liability for any direct or indirect loss or damage or, in particular, for lost profit, which you may incur as a result of the use and existence of the information provided within this Report.


To contact us please email rick@aheadoftheherd.com

Ahead of the Herd
www.aheadoftheherd.com